Projected survival from 12-month landmark. Patients achieving partial (PCyR) or complete cytogenetic response (CCyR) by 12 months had significantly superior projected survival than patients with minor cytogenetic response (miCyR) or complete hematologic response (CHR; 97% vs 84% at 1 year, P = .02), who in turn had similar projected survival as patients with hematologic failure (88% at 1 year, P = .89).